Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
3.990
-0.360 (-8.28%)
Dec 20, 2024, 4:00 PM EST - Market closed
Valneva SE Employees
Valneva SE had 676 employees as of December 31, 2023. The number of employees decreased by 43 or -5.98% compared to the previous year.
Employees
676
Change (1Y)
-43
Growth (1Y)
-5.98%
Revenue / Employee
$261,565
Profits / Employee
-$12,239
Market Cap
325.42M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AngioDynamics | 748 |
Spok Holdings | 384 |
Kamada | 378 |
Prime Medicine | 234 |
NeuroPace | 171 |
Absci | 155 |
Olema Pharmaceuticals | 74 |
Design Therapeutics | 58 |
VALN News
- 2 days ago - Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India - GlobeNewsWire
- 17 days ago - Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal - GlobeNewsWire
- 18 days ago - Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 25 days ago - Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA - GlobeNewsWire
- 5 weeks ago - European And US Vaccine Stocks Are Under Pressure - Here's WHy - Benzinga
- 5 weeks ago - Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 - GlobeNewsWire
- 6 weeks ago - Valneva SE (VALN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire